nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

Home nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

/ Publications

Share the Post

About the Author

Related Posts

New Drug Trial Gives Hope for Treatment-Resistant Epilepsy
Read More
Richard Maroun, JD
Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 (FYARRO™) in Greater China
Read More
Bryan Ball
cache
Read More
Scott Giacobello, CPA
Analysis of inactivating TSC1 and TSC2 alterations in a real-world patient population with advanced gynecological cancers in the Foundation Medicine genomic database
nab-Sirolimus improves mTOR pathway suppression and antitumor activity versus oral mTOR inhibitors in PTEN null bladder cancer (UMUC3) and TSC2 null liver cancer (SNU398) xenografts

Comments

Comments are closed.